A cohort study of antihypertensive medication use and breast cancer among Danish women

Breast Cancer Research and Treatment

Volumn 97, Issue 3, 2006, Pages 231-236

  Fryzek, Jon P ^a   Poulsen, Aslak H ^b   Lipworth, Loren ^a   Pedersen, Lars ^c   Nørgaard, Mette ^c   McLaughlin, Joseph K ^a   Friis, Søren ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antihypertensive medications; Breast cancer; Cohort; Epidemiology

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM SPARING DIURETIC AGENT; SULFONAMIDE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; DENMARK; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BREAST NEOPLASMS; CALCIUM CHANNEL BLOCKERS; DENMARK; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; REGISTRIES; RISK ASSESSMENT; RISK FACTORS;

EID: 33745380780     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9091-x     Document Type: Article

References (23)

1. Kizer JR, Kimmel SE: Epidemiologic review of the calcium channel blocker drugs An up-to-date perspective on the proposed hazards. Arch Intern Med 161(9): 1145-1158, 2001
2. Felmeden DC, Lip GYH: Antihypertensive therapy and cancer risk. Drug Safety 24(10): 727-739, 2001
3. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL: Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 80(8): 1438-1447, 1997
4. Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL, Andersen M, Fraumeni JF Jr, Olsen J: Cancer risk in users of calcium channel blockers. Hypertension 29(5): 1091-1094, 1997
5. Sorensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH, McLaughlin JK, Baron JA: Cancer risk and mortality in users of calcium channel blockers A cohort study. Cancer 89(1): 165-170, 2000
6. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR: Calcium-channel blockers and risk of cancer. Lancet 349: 525-528, 1997
7. Meier CR, Derby LE, Jick SS, Jick H: Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 160: 349-353, 2000
8. Lever AF, Hole DJ, Gillis CR, et al.: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 351: 1292-1296, 1998
9. Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC: Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 63(3): 573-578, 2003
10. Yuan JM, Koh WP, Sun CL, Lee HP, Yu MC: Green tea intake, ACE gene polymorphism and breast cancer risk among Chinese women in Singapore. 2005 Mar 31; [Epub ahead of print]
11. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH: Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92(9): 2462-2470, 2001
12. Stahl M, Bulpitt CJ, Palmer AJ, Beevers DG, Coles EC, Webster J: Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP). J Hum Hypertens 14(5): 285-286, 2000
13. Grossman E, Messerli FH, Goldbourt U: Antihypertensive therapy and the risk of malignancies. Eur Heart J 22(15): 1343-1352, 2001
14. Capella D: Descriptive tools and analysis. In: Dukes MNG (ed.) Drug Utilization Studies: Methods and Uses. WHO regional publications (European series no. 45). World Health Organization, Geneva 1993, pp 55-78
15. The WHO Collaborating Centre for Drug Statistics Methodology [Internet]. Oslo, Norway: Norwegian Institute of Public Health; [updated 2004 Jan 5; cited 2004 Jul 27]. Available from: http://www.whocc.no/atcddd/
16. Storm HH, Michelsen EV, Clemmensen IH, Pihl J: The Danish Cancer Registry-history, content, quality, and use. Dan Med Bull 44: 535-539, 1997
17. Gaist D, Sorensen HT, Hallas J.: The Danish prescription registries. Dan Med Bull 44: 445-448, 1997
18. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR: Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 98(7): 1504-5113, 2003
19. Gonzalez-Perez A, Ronquist G, Garcia Rodriguez LA: Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 13(8): 581-585, 2004
20. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, Warshauer ME, Shapiro S: Calcium channel blockers and the risk of cancer. JAMA 279(13): 1000-1004, 1998
21. Jonas M, Goldbourt U, Boyko V, Mandelzweig L, Behar S, Reicher-Reiss H: Nifedipine and cancer mortality: 10-year follow-up of 2607 patients after acute myocardial infarction. Cardiovasc Drugs Ther 12(2): 177-181, 1998
22. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, Wallace RB, Havlik RJ: Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348(9026): 493-497, 1996
23. Hole DJ, Hawthorne VM, Isles CG, McGhee SM, Robertson JWK, Gillis CR, Wapshaw JA, Lever AF: Incidence of and mortality from cancer in hypertensive patients. BMJ 306: 609-611, 1993